Regeneron Pharmaceuticals Management
Management criteria checks 4/4
Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 36.17 years. total yearly compensation is $7.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 2.25% of the company’s shares, worth $2.34B. The average tenure of the management team and the board of directors is 5.6 years and 17.3 years respectively.
Key information
Leonard Schleifer
Chief executive officer
US$7.0m
Total compensation
CEO salary percentage | 25.9% |
CEO tenure | 36.2yrs |
CEO ownership | 2.3% |
Management average tenure | 5.6yrs |
Board average tenure | 17.3yrs |
Recent management updates
Recent updates
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 07Regeneron Pharmaceuticals (NASDAQ:REGN) Has A Pretty Healthy Balance Sheet
Jul 17Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Apr 17Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$4b |
Sep 30 2023 | n/a | n/a | US$4b |
Jun 30 2023 | n/a | n/a | US$4b |
Mar 31 2023 | n/a | n/a | US$4b |
Dec 31 2022 | US$7m | US$2m | US$4b |
Sep 30 2022 | n/a | n/a | US$5b |
Jun 30 2022 | n/a | n/a | US$6b |
Mar 31 2022 | n/a | n/a | US$8b |
Dec 31 2021 | US$6m | US$2m | US$8b |
Sep 30 2021 | n/a | n/a | US$7b |
Jun 30 2021 | n/a | n/a | US$6b |
Mar 31 2021 | n/a | n/a | US$4b |
Dec 31 2020 | US$135m | US$1m | US$4b |
Sep 30 2020 | n/a | n/a | US$3b |
Jun 30 2020 | n/a | n/a | US$3b |
Mar 31 2020 | n/a | n/a | US$2b |
Dec 31 2019 | US$21m | US$1m | US$2b |
Sep 30 2019 | n/a | n/a | US$2b |
Jun 30 2019 | n/a | n/a | US$2b |
Mar 31 2019 | n/a | n/a | US$2b |
Dec 31 2018 | US$27m | US$1m | US$2b |
Sep 30 2018 | n/a | n/a | US$2b |
Jun 30 2018 | n/a | n/a | US$2b |
Mar 31 2018 | n/a | n/a | US$1b |
Dec 31 2017 | US$27m | US$1m | US$1b |
Compensation vs Market: Leonard's total compensation ($USD7.00M) is below average for companies of similar size in the US market ($USD12.18M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard Schleifer (70 yo)
36.2yrs
Tenure
US$7,004,069
Compensation
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 36.2yrs | US$7.00m | 2.25% $ 2.3b | |
Co-Founder | 23.2yrs | US$6.59m | 1.22% $ 1.3b | |
Executive Vice President of Research | 5.2yrs | US$9.12m | 0.049% $ 50.7m | |
Executive VP and GM of Industrial Operations & Product Supply | 15.9yrs | US$8.85m | 0.031% $ 32.6m | |
Executive Vice President of Commercial | 6.1yrs | US$6.90m | 0.013% $ 13.1m | |
Senior VP of Finance & CFO | 3.2yrs | no data | 0.023% $ 23.6m | |
Senior Vice President of Quality Assurance & Operations | 4.2yrs | no data | no data | |
Senior VP of IT & Chief Information Officer | 3.2yrs | no data | no data | |
Senior Vice President of Investor Relations & Strategic Analysis | no data | no data | no data | |
Executive VP | 12.5yrs | US$7.13m | 0.037% $ 38.8m | |
Senior VP & Chief Compliance Officer | 1.2yrs | no data | no data | |
Senior Vice President of Corporate Affairs | no data | no data | no data |
5.6yrs
Average Tenure
63yo
Average Age
Experienced Management: REGN's management team is seasoned and experienced (5.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 36.2yrs | US$7.00m | 2.25% $ 2.3b | |
Co-Founder | 23.2yrs | US$6.59m | 1.22% $ 1.3b | |
Lead Independent Director | 13.3yrs | US$720.03k | 0.00074% $ 767.0k | |
Independent Director | 21.2yrs | US$725.03k | 0.017% $ 17.6m | |
Independent Director | 32.8yrs | US$725.03k | 0.012% $ 12.1m | |
Independent Director | 32.8yrs | US$710.03k | 0.0046% $ 4.8m | |
Independent Director | 36.2yrs | US$720.03k | 0.027% $ 27.5m | |
Independent Director | 7.2yrs | US$705.03k | 0.000010% $ 10.4k | |
Independent Director | 1.4yrs | US$1.02m | 0.00042% $ 435.3k | |
Independent Director | 7.5yrs | US$715.03k | 0% $ 0 | |
Independent Director | 7.5yrs | US$715.03k | 0.0013% $ 1.3m | |
Independent Director | less than a year | no data | no data |
17.3yrs
Average Tenure
70yo
Average Age
Experienced Board: REGN's board of directors are seasoned and experienced ( 17.3 years average tenure).